Compare Unichem Lab with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs WOCKHARDT - Comparison Results

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB WOCKHARDT UNICHEM LAB/
WOCKHARDT
 
P/E (TTM) x -43.9 -77.3 - View Chart
P/BV x 1.1 1.7 62.9% View Chart
Dividend Yield % 1.3 0.0 57,106.1%  

Financials

 UNICHEM LAB   WOCKHARDT
EQUITY SHARE DATA
    UNICHEM LAB
Mar-19
WOCKHARDT
Mar-18
UNICHEM LAB/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs2921,012 28.9%   
Low Rs182532 34.2%   
Sales per share (Unadj.) Rs167.7355.9 47.1%  
Earnings per share (Unadj.) Rs-3.6-60.3 6.0%  
Cash flow per share (Unadj.) Rs5.9-46.8 -12.7%  
Dividends per share (Unadj.) Rs4.000.01 40,000.0%  
Dividend yield (eoy) %1.70 130,253.2%  
Book value per share (Unadj.) Rs372.3257.8 144.4%  
Shares outstanding (eoy) m70.38110.63 63.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.42.2 65.2%   
Avg P/E ratio x-65.3-12.8 509.8%  
P/CF ratio (eoy) x39.9-16.5 -241.7%  
Price / Book Value ratio x0.63.0 21.3%  
Dividend payout %-110.20 664,083.4%   
Avg Mkt Cap Rs m16,68085,379 19.5%   
No. of employees `0002.66.3 41.6%   
Total wages/salary Rs m2,3939,371 25.5%   
Avg. sales/employee Rs Th4,535.26,295.0 72.0%   
Avg. wages/employee Rs Th919.81,498.3 61.4%   
Avg. net profit/employee Rs Th-98.2-1,066.3 9.2%   
INCOME DATA
Net Sales Rs m11,80139,369 30.0%  
Other income Rs m9841,202 81.9%   
Total revenues Rs m12,78540,571 31.5%   
Gross profit Rs m-83518 -4,562.3%  
Depreciation Rs m6741,495 45.1%   
Interest Rs m752,555 2.9%   
Profit before tax Rs m-600-2,830 21.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m-343257 -133.6%   
Profit after tax Rs m-256-6,669 3.8%  
Gross profit margin %-7.10 -15,220.8%  
Effective tax rate %57.3-9.1 -630.6%   
Net profit margin %-2.2-16.9 12.8%  
BALANCE SHEET DATA
Current assets Rs m20,38433,796 60.3%   
Current liabilities Rs m5,02926,917 18.7%   
Net working cap to sales %130.117.5 744.7%  
Current ratio x4.11.3 322.8%  
Inventory Days Days10579 132.0%  
Debtors Days Days13589 151.2%  
Net fixed assets Rs m9,02339,664 22.7%   
Share capital Rs m141553 25.5%   
"Free" reserves Rs m26,05827,968 93.2%   
Net worth Rs m26,19928,522 91.9%   
Long term debt Rs m021,731 0.0%   
Total assets Rs m31,49681,620 38.6%  
Interest coverage x-7.0-0.1 6,487.0%   
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x0.40.5 77.7%   
Return on assets %-0.6-5.0 11.4%  
Return on equity %-1.0-23.4 4.2%  
Return on capital %-2.0-7.7 26.1%  
Exports to sales %69.40-   
Imports to sales %00-   
Exports (fob) Rs m8,188NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m8,1889,807 83.5%   
Fx outflow Rs m5961,789 33.3%   
Net fx Rs m7,5928,019 94.7%   
CASH FLOW
From Operations Rs m-3,278684 -478.9%  
From Investments Rs m-2,8606,302 -45.4%  
From Financial Activity Rs m-24-7,695 0.3%  
Net Cashflow Rs m-4,690-664 706.4%  

Share Holding

Indian Promoters % 50.1 74.5 67.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 2.3 656.5%  
FIIs % 3.0 7.7 39.0%  
ADR/GDR % 0.0 0.1 -  
Free float % 31.7 15.4 205.8%  
Shareholders   20,176 67,757 29.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   BIOCON   CADILA HEALTHCARE  AUROBINDO PHARMA  DR. DATSONS LABS  GLENMARK PHARMA  

Compare UNICHEM LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; TCS & Wipro Rally Over 3.5%(Closing)

Indian share markets recouped early losses during closing hours and ended today's volatile session higher, helped by gains in metals and banking stocks.

Related Views on News

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Apr 15, 2021 03:37 PM

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 5-YR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS